The Senate introduced SR303 as a non-binding resolution expressing support for designating May 17, 2025 as DIPG Pediatric Brain Cancer Awareness Day to raise awareness of diffuse intrinsic pontine glioma and pediatric cancers and to encourage related research. The measure is ceremonial in nature: it designates a day, explains the stakes around DIPG, and calls for greater public understanding and action in research and care.
There is no funding authorization or regulatory mandate attached to the resolution, and its impact relies on awareness and voluntary actions by researchers, clinicians, and advocacy groups.
At a Glance
What It Does
The resolution designates May 17, 2025 as DIPG Pediatric Brain Cancer Awareness Day and expresses Senate support for understanding DIPG, developing treatments, and providing comprehensive care.
Who It Affects
DIPG patients and their families; pediatric brain cancer researchers and clinicians; advocacy organizations and hospitals that treat or support affected children.
Why It Matters
DIPG has a disproportionately severe impact on children, with few survivors and limited progress over decades. A formal designation can elevate awareness, mobilize private funding, and focus public attention on the need for research and coordinated care, even though it does not create new spending or mandates.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SR303 is a ceremonial Senate resolution recognizing the urgency of DIPG and pediatric brain cancer. It designates a national awareness day on May 17, 2025, to highlight DIPG and to catalyze interest in research and better care practices for affected children and their families.
The preamble documents the grim realities of DIPG — hundreds of children affected each year, low survival rates, and a long-standing lack of significant improvement in outcomes. The core action is political and symbolic: express support for understanding DIPG, advancing research for treatments, and ensuring comprehensive care for patients and families.
The Five Things You Need to Know
The bill designates May 17, 2025 as DIPG Pediatric Brain Cancer Awareness Day.
It expresses Senate support for understanding DIPG, developing treatments, and providing comprehensive care.
DIPG affects about 200-300 U.S. children each year; median survival after diagnosis is ~11 months; 5-year survival is around 2%.
The measure is ceremonial and does not authorize spending or impose new duties.
Sponsored by Senator Reed with Senator Fischer as co-sponsor; introduced in the 119th Congress.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation of DIPG Awareness Day
The Senate designates May 17, 2025 as DIPG Pediatric Brain Cancer Awareness Day. This is a ceremonial designation intended to elevate public awareness and encourage engagement by researchers, clinicians, patients, and families. The resolution does not create any legal obligations or funding requirements.
Support for Research, Treatments, and Comprehensive Care
The Senate expresses support for efforts to better understand DIPG and to develop effective treatments, as well as to provide comprehensive care for children with DIPG and their families. The language signals policy interest and alignment with ongoing research and clinical care priorities but does not allocate resources or mandate actions by agencies or private entities.
Public Awareness and Education
The resolution encourages all Americans to become more informed about DIPG, pediatric brain cancer in general, and the challenges related to research. It emphasizes education and awareness as catalysts for advocacy, philanthropy, and potential future policy attention.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Families of DIPG patients who gain access to heightened awareness and potentially more information and support networks
- Pediatric brain cancer researchers and academic medical centers focusing on DIPG
- DIPG advocacy groups and patient organizations that benefit from visibility and public engagement
- Hospitals and pediatric oncology departments that may see greater public attention and potential collaboration
Who Bears the Cost
- No direct federal spending or mandated actions are described in the resolution
- Private sector and nonprofit groups may incur minor costs if they choose to observe or sponsor awareness events
- No new state or local mandates are imposed by this measure
- Hospitals and schools may voluntarily participate in awareness activities with anticipated, but non-mandated, costs
Key Issues
The Core Tension
Symbolic recognition versus material action: the designation raises awareness but does not secure funding or mandates, leaving future progress to private philanthropy and research ecosystems while policymakers decide whether and how to translate attention into concrete policy.
The bill is ceremonial and does not authorize funding or create regulatory obligations. Its value rests in signaling national attention to DIPG and pediatric brain cancer, which could influence private fundraising, research collaboration, and public understanding.
A potential tension exists between symbolic recognition and the allocation of real resources for patient care and research; without accompanying policy action or funding, the day’s impact depends on private and nonprofit actors and on the public’s and professionals’ engagement.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.